1176 related articles for article (PubMed ID: 26917821)
1. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
Finks SW; Trujillo TC; Dobesh PP
Ann Pharmacother; 2016 Jun; 50(6):486-501. PubMed ID: 26917821
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
[TBL] [Abstract][Full Text] [Related]
3. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
Weitz JI; Jaffer IH
Pol Arch Med Wewn; 2016 Sep; 126(9):688-696. PubMed ID: 27592622
[TBL] [Abstract][Full Text] [Related]
4. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
5. Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.
Imberti D; Mastroiacovo D
Intern Emerg Med; 2017 Aug; 12(5):561-563. PubMed ID: 28647891
[TBL] [Abstract][Full Text] [Related]
6. Considerations for Prescribing Target-Specific Oral Anticoagulants in the Setting of Renal Dysfunction or Drug Interactions.
Pan EY; Sobieraj DM
Conn Med; 2016 Feb; 80(2):105-11. PubMed ID: 27024982
[No Abstract] [Full Text] [Related]
7. Modern Treatment Modalities and Duration of Treatment for Venous Thromboembolism.
Robert-Ebadi H; Righini M
Ther Umsch; 2016; 73(10):618-625. PubMed ID: 28045360
[No Abstract] [Full Text] [Related]
8. Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long?
Howard LS
Expert Rev Respir Med; 2018 May; 12(5):387-402. PubMed ID: 29542359
[TBL] [Abstract][Full Text] [Related]
9. New oral anticoagulants for the treatment of venous thromboembolism.
Agnelli G; Becattini C; Franco L
Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
[TBL] [Abstract][Full Text] [Related]
10. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Robertson L; Kesteven P; McCaslin JE
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010957. PubMed ID: 26636644
[TBL] [Abstract][Full Text] [Related]
11. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
Khorana AA; Noble S; Lee AYY; Soff G; Meyer G; O'Connell C; Carrier M
J Thromb Haemost; 2018 Sep; 16(9):1891-1894. PubMed ID: 30027649
[No Abstract] [Full Text] [Related]
12. Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study.
Goldhaber SZ; Ageno W; Casella IB; Chee KH; Schellong S; Singer DE; Desch M; Reilly PA; Donado E; Tang W; Voccia I; Schulman S
Am J Med; 2020 Aug; 133(8):936-945. PubMed ID: 32325043
[TBL] [Abstract][Full Text] [Related]
13. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
[TBL] [Abstract][Full Text] [Related]
14. Thromboembolic Events While Taking Direct Oral Anticoagulants: An Analysis of Post-market WHO Database Reports from 2012 to 2020.
Mitrovic D; Emmens W; Naimi A; van der Mijle A; Veeger N; van Roon E; van den Bemt P
Clin Drug Investig; 2022 Jul; 42(7):593-598. PubMed ID: 35675030
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
16. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Voigtlaender M; Langer F
Hamostaseologie; 2017 Oct; 37(4):241-255. PubMed ID: 28508916
[TBL] [Abstract][Full Text] [Related]
17. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants.
Rosovsky R; Merli G
Tech Vasc Interv Radiol; 2017 Sep; 20(3):141-151. PubMed ID: 29029708
[TBL] [Abstract][Full Text] [Related]
20. The Role of New Oral Anticoagulants (NOACs) in Cancer Patients.
Ravikumar R; Lim CS; Davies AH
Adv Exp Med Biol; 2017; 906():137-148. PubMed ID: 27620312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]